Renibus has completed subject enrolment for the Phase III PROTECT trial of RBT-1 in minimising post-operative risk in cardiac ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

Clinical ink has launched the AI-powered, fully integrated analytics dashboard, TrialLens, which is designed to interpret ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial of ...

Akeso and Summit's drug previously beat Keytruda in a separate Phase III study, extending PFS by five months. Akeso ...

Lokavant has launched the AI-powered clinical trial forecasting solution, Spectrum v15, to dispel uncertainty in the ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an IDMC.

The US FDA has cleared the IND application of Aclaris to commence the placebo-controlled Phase Ia/Ib study of the ATI-052 ...

Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.

Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...